Clinical Trial

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-13; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-02
Trial Details
NCT Number NCT07231211
Lead Sponsor Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions Solid Tumors
Enrollment 258 participants
Start Date 2025-11-20
Primary Completion 2026-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24